16-291 Search Results


b7181440  (ATCC)
90
ATCC b7181440
Characterization of VREfm parental isolates and derived mutants that survived daptomycin challenge in the in vitro PK/PD model
B7181440, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b7181440/product/ATCC
Average 90 stars, based on 1 article reviews
b7181440 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
apto 253  (MedChemExpress)
93
MedChemExpress apto 253
Characterization of VREfm parental isolates and derived mutants that survived daptomycin challenge in the in vitro PK/PD model
Apto 253, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apto 253/product/MedChemExpress
Average 93 stars, based on 1 article reviews
apto 253 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
charcoal denuder  (BOC Sciences)
90
BOC Sciences charcoal denuder
Characterization of VREfm parental isolates and derived mutants that survived daptomycin challenge in the in vitro PK/PD model
Charcoal Denuder, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/charcoal denuder/product/BOC Sciences
Average 90 stars, based on 1 article reviews
charcoal denuder - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-4isoxazolecarboxamide 16291  (Cayman Chemical)
90
Cayman Chemical 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-4isoxazolecarboxamide 16291
Characterization of VREfm parental isolates and derived mutants that survived daptomycin challenge in the in vitro PK/PD model
3 (2 Chlorophenyl) N (4 Chlorophenyl) N,5 Dimethyl 4isoxazolecarboxamide 16291, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-4isoxazolecarboxamide 16291/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-4isoxazolecarboxamide 16291 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Characterization of VREfm parental isolates and derived mutants that survived daptomycin challenge in the in vitro PK/PD model

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection

doi: 10.1128/AAC.01265-17

Figure Lengend Snippet: Characterization of VREfm parental isolates and derived mutants that survived daptomycin challenge in the in vitro PK/PD model

Article Snippet: The projected total AUC 0–24 /MIC ratio for VREfm ATCC 51559 and B7181440 is 953 (ƒAUC 0–24 of 162, 91.5% protein binding, and daptomycin MICs of 2 μg/ml), an exposure that exceeded the cutoff value but did not prevent emergence of reduced susceptibility.

Techniques: Derivative Assay, In Vitro, Mutagenesis

Pharmacodynamic activity of daptomycin and oritavancin at free-drug exposures associated with 12 mg/kg/day daptomycin (green triangles) and a single 1,200-mg dose of oritavancin (blue circles) against the clinical isolates of VanA VREfm ATCC 51559 (A), B7181440 (B), and B7231527 (C) in an in vitro PK/PD model over 72 h. Mean values ± standard deviation (SD) are from two independent experiments done in duplicate. Control cultures are shown for each isolate (black diamonds), using the flow rates for oritavancin to supply fresh drug-free medium over 24 h. The inset in panel A depicts the single occurrence of regrowth of ATCC 51559 following exposure to daptomycin. The inset in panel C depicts the single occurrence of eradication of B7231527 following exposure to daptomycin. The dashed line indicates the limit of detection (<66.7 CFU/ml).

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection

doi: 10.1128/AAC.01265-17

Figure Lengend Snippet: Pharmacodynamic activity of daptomycin and oritavancin at free-drug exposures associated with 12 mg/kg/day daptomycin (green triangles) and a single 1,200-mg dose of oritavancin (blue circles) against the clinical isolates of VanA VREfm ATCC 51559 (A), B7181440 (B), and B7231527 (C) in an in vitro PK/PD model over 72 h. Mean values ± standard deviation (SD) are from two independent experiments done in duplicate. Control cultures are shown for each isolate (black diamonds), using the flow rates for oritavancin to supply fresh drug-free medium over 24 h. The inset in panel A depicts the single occurrence of regrowth of ATCC 51559 following exposure to daptomycin. The inset in panel C depicts the single occurrence of eradication of B7231527 following exposure to daptomycin. The dashed line indicates the limit of detection (<66.7 CFU/ml).

Article Snippet: The projected total AUC 0–24 /MIC ratio for VREfm ATCC 51559 and B7181440 is 953 (ƒAUC 0–24 of 162, 91.5% protein binding, and daptomycin MICs of 2 μg/ml), an exposure that exceeded the cutoff value but did not prevent emergence of reduced susceptibility.

Techniques: Activity Assay, In Vitro, Standard Deviation, Control

Mean changes in bacterial viability relative to inoculum of the tested VREfm isolates exposed to daptomycin and oritavancin in the in vitro PK/PD model

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection

doi: 10.1128/AAC.01265-17

Figure Lengend Snippet: Mean changes in bacterial viability relative to inoculum of the tested VREfm isolates exposed to daptomycin and oritavancin in the in vitro PK/PD model

Article Snippet: The projected total AUC 0–24 /MIC ratio for VREfm ATCC 51559 and B7181440 is 953 (ƒAUC 0–24 of 162, 91.5% protein binding, and daptomycin MICs of 2 μg/ml), an exposure that exceeded the cutoff value but did not prevent emergence of reduced susceptibility.

Techniques: In Vitro